|
Post by JHam on Apr 16, 2020 10:03:57 GMT
|
|
|
Post by JHam on Apr 16, 2020 10:38:33 GMT
|
|
|
Post by selluwud on Apr 16, 2020 11:36:32 GMT
Interesting,someone in the field of diagnostics will come out a winner before this is all over.
|
|
|
Post by selluwud on Apr 16, 2020 14:22:58 GMT
Do you have a target price you're looking to enter at?
|
|
|
Post by JHam on Apr 16, 2020 17:26:30 GMT
Do you have a target price you're looking to enter at? I was hoping for a retraction to the high $5s/low $6s, but I went ahead and opened a small position at $6.70 just to get my toes wet.
|
|
|
Post by selluwud on Apr 16, 2020 17:51:06 GMT
I have a limit order for 6.60 if it hits. Small position as well.
|
|
|
Post by selluwud on Apr 16, 2020 19:32:11 GMT
I have a limit order for 6.60 if it hits. Small position as well. Now that it filled I'm sure it'll go to hell. LOL
|
|
|
Post by JHam on Apr 17, 2020 5:10:54 GMT
I have a limit order for 6.60 if it hits. Small position as well. Now that it filled I'm sure it'll go to hell. LOL I'll be suffering right along with you I have a small position but looking to add tomorrow on any dip. I like this stock because their base business is sound and undervalued at the moment. Like a lot of these biotechs, coronavirus provided an unforeseen "opportunity" (sucks to say that) that has the potential to create massive value for them. I was just watching a doctor on CNN discuss the need for mass antibody testing before we truly can get back to normal. Each Mosaic screening machine can run 3,000 tests per day. That's 1M tests per year, for 1 machine! 30 machines would yield 30M tests per year, which is their goal. $15 per test (the company said it would be between $15-$25 per test) would come to $450M in revenue give or take. Less than half of that though would still be a big deal for their bottom line. The margins here are ridiculous. Microarrays like Mosaic cost about $1 to make and according to slides 26 and 27 on the corporate presentation they have a 50-60% EBIT margin. Plus a 10% tax rate. Keep in mind, and Coronavirus is getting priority and the attention right now, but their core business won't really get rolling until next year.
|
|
|
Post by JHam on Apr 17, 2020 5:48:35 GMT
One last thing, they will have to start in the EU on a RUO (research-use only) label, then wait for FDA approval before being able to expand to the US. Hopefully that won't take too long. The more I read, the more I like.
|
|
|
Post by JHam on Apr 17, 2020 5:57:42 GMT
I have a limit order for 6.60 if it hits. Small position as well. Now that it filled I'm sure it'll go to hell. LOL If it makes you feel any better, Jospeh Edelman has been buying in the mid $6s and even last Nov. at $7.00. So we're in good company www.openinsider.com/search?q=QTNT
|
|
|
Post by JHam on Apr 17, 2020 13:20:36 GMT
Here is the investor presentation given on March 25th that goes with the slide deck above. The CEO talks about how back during the SARS when he was in Singapore working for Roche, they created test and strategically distributed 30 of them on a RUO basis. The tests proved very accurate creating a big demand which put pressure on regulatory authorities to grant expedited approval. He said that is the same plan now. investors.quotientbd.com/events-and-presentations
|
|
|
Post by selluwud on Apr 17, 2020 13:28:05 GMT
Here is the investor presentation given on March 25th that goes with the slide deck above. The CEO talks about how back during the SARS when he was in Singapore working for Roche, they created test and strategically distributed 30 of them on a RUO basis. The tests proved very accurate creating a big demand which put pressure on regulatory authorities to grant expedited approval. He said that is the same plan now. investors.quotientbd.com/events-and-presentationsI'll check it out later at home. Thanks.
|
|
|
Post by actcrazy on Apr 18, 2020 18:40:39 GMT
I like how the ticker starts with a Q followed with TNT . Explosion? Awaken World....GLTA Here!
|
|
|
Post by JHam on Apr 21, 2020 13:59:08 GMT
Someone just gave a quick summary of a new Cowen report:
$14 PT
"Recent Discussions With Management Bolster our Confidence in QTNT's COVID-19 Efforts" - Initial rollout of the test slated for early May. Receiving "considerable" interest from parties throughout Europe and US
|
|
|
Post by magnus123 on Apr 21, 2020 17:01:51 GMT
I picked up some shares last week as well. Maybe a little bit to expensive at $6.60. But this looks really interesting.
|
|
|
Post by JHam on Apr 21, 2020 17:24:56 GMT
I picked up some shares last week as well. Maybe a little bit to expensive at $6.60. But this looks really interesting. Better than my average of $6.82. If things go the way we expect a few pennies difference won’t matter.
|
|
|
Post by JHam on Apr 21, 2020 20:11:44 GMT
|
|
|
Post by JHam on Apr 21, 2020 20:12:54 GMT
Quotient Limited Announces SARS-CoV-2 (COVID-19) Antibody Test Performance Update
April 21, 2020 16:05 ET JERSEY, Channel Islands, April 21, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT ), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive performance data for its SARS-CoV-2 antibody test. Based on these results, under applicable regulations, the Company can now offer the MosaiQ COVID-19 Antibody Microarray as a research-use-only (RUO) product in Europe and the US.
MosaiQ COVID-19 Antibody Microarray Performance
A summary of the interim study results using greater than 160 samples for the MosaiQ COVID-19 Antibody Microarray are set out below:
Pathogen Sensitivity % Specificity % SARS-CoV-2 100% 95%
“While the test is now available for research use only, the Company will continue internal and external studies. We expect to achieve the CE Mark in the coming weeks, permitting broader distribution and use in Europe. Quotient also plans to seek emergency use authorization in the US, following guidelines established by the U.S. Food and Drug Administration (FDA). With FDA authorization, broader use would be permitted in the US as well,” said Franz Walt, Chief Executive Officer of Quotient.
|
|
|
Post by JHam on Apr 21, 2020 20:23:20 GMT
Just in case anyone is unfamiliar...
Sensitivity = true positive rate
Specificity = true negative rate
In other words. If you have COVID-19 you will test positive 100% for certain. However, 5% of people who do not have COVID-19 will get false positives. That’s actually a great number, and in line with what they were anticipating. The CEO said on the call that they should be able to tweak it to get the specificity even closer to 100%. Remember this is an antibody test.
|
|
|
Post by vzveteran on Apr 21, 2020 21:55:53 GMT
Trading @ 7.10 after hours...
|
|